CLDX — Celldex Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.35bn
- $673.85m
- $7.02m
- 54
- 13
- 10
- 14
Annual cashflow statement for Celldex Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -59.8 | -70.5 | -112 | -141 | -158 |
| Depreciation | |||||
| Non-Cash Items | 15.7 | 7.59 | 9.6 | 17.7 | 18.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.299 | -1.05 | -3.9 | 13.5 | -21.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -40.4 | -60.9 | -104 | -107 | -158 |
| Capital Expenditures | -1.55 | -1.25 | -1.83 | -1.82 | -1.92 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -96.7 | -215 | 91.8 | -104 | -288 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -98.2 | -216 | 89.9 | -106 | -290 |
| Financing Cash Flow Items | 0.434 | 2.48 | 4.08 | 2.24 | 9.15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 171 | 272 | 4.08 | 218 | 441 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 32.6 | -4.69 | -9.71 | 5.38 | -6.46 |